TopiVert

About TopiVert

TopiVert is a private, clinical-stage biotechnology company focused on developing next-generation Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, topical, non-systemic medicines for the treatment of chronic inflammatory diseases. The company operates primarily in the healthcare and pharmaceutical markets, targeting conditions such as dry eye disease and ulcerative colitis.

TopiVert's core technology revolves around NSKIs, which are small molecules designed to selectively target specific kinases involved in inflammatory processes. This targeted approach aims to provide long-term safety and tolerability by minimizing systemic exposure. The company's lead product, TOP1630, is being developed for dry eye disease, a prevalent and often chronic condition that can be debilitating in severe cases. TOP1630 has already shown promising results in a Phase 1/2a proof of concept study in the United States.

Another key product in TopiVert's pipeline is TOP1890, which is being developed for ulcerative colitis, a condition where first-line therapy fails in 50% of patients, and 15% require major colon surgery. TOP1890 is set to enter a Phase 1 study with an oral formulation.

TopiVert's business model involves advancing its clinical pipeline through various stages of development, with the aim of eventually partnering with larger pharmaceutical companies for commercialization. The company generates revenue through research grants, milestone payments, and potential future royalties from partnered products.